MAPT and Alzheimer disease: Although there are currently no clinical trials using CRISPR/Cas9 for Alzheimer’s disease (AD), this gene-editing technology holds significant potential for targeting genes that regulate amyloid beta (Aβ) and tau proteins, two key pathological features of AD.